HN2012001011A - Compuestos de espiropiperidina como antagonistas del receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas del receptor orl-1

Info

Publication number
HN2012001011A
HN2012001011A HN2012001011A HN2012001011A HN2012001011A HN 2012001011 A HN2012001011 A HN 2012001011A HN 2012001011 A HN2012001011 A HN 2012001011A HN 2012001011 A HN2012001011 A HN 2012001011A HN 2012001011 A HN2012001011 A HN 2012001011A
Authority
HN
Honduras
Prior art keywords
orl
spyropiperidine
antrogonists
receptor
compounds
Prior art date
Application number
HN2012001011A
Other languages
English (en)
Spanish (es)
Inventor
Diaz Buezo Nuria
Benito Collado Ana Belen
Jimenez Aguado Alma Maria
La Fuente Blanco Cecilia
Martinez-Grau Maria Angeles
Pedregal-Tercero Concepcion
Toledo Escribano Miguel Angel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2012001011A publication Critical patent/HN2012001011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HN2012001011A 2009-11-16 2012-05-11 Compuestos de espiropiperidina como antagonistas del receptor orl-1 HN2012001011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
HN2012001011A true HN2012001011A (es) 2015-08-31

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012001011A HN2012001011A (es) 2009-11-16 2012-05-11 Compuestos de espiropiperidina como antagonistas del receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (https=)
EP (1) EP2501703B1 (https=)
JP (1) JP5680101B2 (https=)
KR (1) KR101363830B1 (https=)
CN (1) CN102612520B (https=)
AR (1) AR078863A1 (https=)
AU (1) AU2010319581C1 (https=)
CA (1) CA2796161C (https=)
CO (1) CO6541545A2 (https=)
CR (1) CR20130087A (https=)
DK (1) DK2501703T3 (https=)
DO (1) DOP2012000135A (https=)
EA (1) EA020848B1 (https=)
EC (1) ECSP12011902A (https=)
ES (1) ES2435814T3 (https=)
HN (1) HN2012001011A (https=)
HR (1) HRP20130967T1 (https=)
IL (1) IL219370A (https=)
JO (1) JO2887B1 (https=)
MA (1) MA33751B1 (https=)
ME (1) ME01537B (https=)
MX (1) MX2012005691A (https=)
MY (1) MY160665A (https=)
NZ (1) NZ600006A (https=)
PE (1) PE20121430A1 (https=)
PH (1) PH12012500969A1 (https=)
PL (1) PL2501703T3 (https=)
PT (1) PT2501703E (https=)
RS (1) RS53018B (https=)
SI (1) SI2501703T1 (https=)
TW (1) TWI465453B (https=)
UA (1) UA107943C2 (https=)
WO (1) WO2011060035A1 (https=)
ZA (1) ZA201202967B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
CR20190436A (es) 2012-10-02 2019-10-29 Bayer Cropscience Ag COMPUESTOS HETEROCICLICOS COMO PLAGUICIDAS (Divisional 2015-0182)
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US6686370B2 (en) * 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
KR100628292B1 (ko) * 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
WO2003010168A1 (fr) * 2001-07-23 2003-02-06 Banyu Pharmaceutical Co., Ltd. Derive de 4-oxoimidazolidine-2-spiropiperidine
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
NZ538307A (en) * 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
AU2009228647B2 (en) * 2008-03-27 2013-07-04 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives

Also Published As

Publication number Publication date
US20110118251A1 (en) 2011-05-19
KR101363830B1 (ko) 2014-02-14
RS53018B (sr) 2014-04-30
WO2011060035A1 (en) 2011-05-19
EP2501703B1 (en) 2013-09-18
AU2010319581C1 (en) 2014-05-15
JP2013510859A (ja) 2013-03-28
SI2501703T1 (sl) 2013-11-29
AU2010319581A1 (en) 2012-06-07
NZ600006A (en) 2014-05-30
MY160665A (en) 2017-03-15
CO6541545A2 (es) 2012-10-16
ECSP12011902A (es) 2012-07-31
CR20130087A (es) 2013-04-17
KR20130026523A (ko) 2013-03-13
DOP2012000135A (es) 2012-08-15
EP2501703A1 (en) 2012-09-26
PL2501703T3 (pl) 2014-02-28
IL219370A (en) 2015-01-29
CN102612520A (zh) 2012-07-25
JO2887B1 (en) 2015-03-15
PE20121430A1 (es) 2012-10-26
PH12012500969A1 (en) 2013-01-07
AU2010319581B2 (en) 2013-12-19
ES2435814T3 (es) 2013-12-23
PT2501703E (pt) 2013-11-26
DK2501703T3 (da) 2013-10-14
MA33751B1 (fr) 2012-11-01
ME01537B (me) 2014-04-20
US8232289B2 (en) 2012-07-31
AR078863A1 (es) 2011-12-07
UA107943C2 (xx) 2015-03-10
HK1169988A1 (en) 2013-02-15
MX2012005691A (es) 2012-06-13
IL219370A0 (en) 2012-06-28
TW201127841A (en) 2011-08-16
CA2796161C (en) 2015-03-17
CA2796161A1 (en) 2011-05-19
EA020848B1 (ru) 2015-02-27
CN102612520B (zh) 2015-04-08
HRP20130967T1 (hr) 2013-11-22
EA201290352A1 (ru) 2012-10-30
JP5680101B2 (ja) 2015-03-04
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
HN2012001011A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CU24045B1 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
ECSP12011581A (es) Inhibidores de bace
MX2019003738A (es) Compuestos antivirales.
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
PT2744765T (pt) Ternesite como aditivo de cimento portland
CR20150370A (es) Compuestos antivirales
CR20130625A (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CR20130118A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
UY34798A (es) Polipéptidos de unión a receptores de quimiocinas
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
BR112014000087A2 (pt) derivados de amina cíclica como antagonistas do receptor ep4
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
CR20150144A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
NI201300125A (es) Derivados de 2 - amino - 3 - ( imidazol - 2 - il ) - piridin - 4 - ona y su uso como inhibidores de cinasa del receptor vegf.
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
DK2606042T3 (da) Disubstituerede tetrahydrofuranyl-forbindelser som antagonister af bradykinin-b1-receptor
UY34403A (es) Preparación de liberación sostenida
BRPI1008008A2 (pt) usos de antagonistas do receptor de nk
CO6761385A2 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mglur 2/3
CL2015000038A1 (es) Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios.